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A series of novel Zn(II) complexes [Zn2(nap)4] (1), [Zn(nap)21,10-phen](2), [Zn(nap)22,9-dmphen] (3),
[Zn(nap)2(2-ampy)2] (4), [Zn(nap)2(imid)2] (5), [Zn(nap)2(1,2-dmimid)2] (6) (nap ¼ naproxen, 1,10-
phen ¼ 1,10-phenanthroline, 2,9-dmphen ¼ 2,9-dimethyl-1,10-phenanthroline, 2-ampy ¼ 2-
aminopyridine, imid ¼ imidazole, 1,2-dmimid ¼ 1,2-dimethyl imidazole) were synthesized and charac-
terized using IR, UVeVis, 1H NMR, 13C{1H} NMR spectroscopy. The crystal structure of complex 3 was
determined using single-crystal X-ray diffraction. In order to assess the effect of the metal ions on the
anti-bacterial activity, complexes 1e6 have been screened in vitro, against (Gþ) bacteria (Staphylococcus
aureus andMicrococcus luteus) and (G) bacteria (Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus
mirabilis and Escherichia coli) using the agar well diffusion method. Complex 2was the only complex that
showed antibacterial activity against P. aeruginosa, where the complexation of the parent ligand 1,10-
phenathroline enhanced signiﬁcantly the activity. All the complexes showed different activity against
the different bacteria, and were compared with activity of the parent ligands. The complexes were tested
also for their anti-malarial activity using two methods: a semi-quantitative micro-assay and a previously
self-developed quantitative in-vitromethod. Both were used to study the efﬁciency of these complexes in
inhibiting the formation of the Malaria pigment. This is considered an important target of many known
anti-malarial drugs such as Chloroquine and Amodaquine. Results showed that the efﬁciency of complex
3 in preventing the formation of b-hematin was 75%. The efﬁciency of Amodiaquine as a standard drug
was reported to give 92.5.
© 2014 Elsevier Masson SAS. All rights reserved.1. Introduction
Zinc is one of themost important trace elements in the body and
it is considered an essential element for many processes in living
organisms [1e3]. Zinc ions exist primarily in the form of complexes
with proteins and nucleic acids and participate in all aspects of
intermediary metabolism, transmission and regulation of the
expression of genetic information, storage, synthesis and action of
peptide hormones and structural maintenance of chromatin, bio-
membranes and extracellular matrices [4]. Zinc ions possess some
anti-bacterial effects, good thermal and color stability with low cost
and little toxicity [5]. The growth of Escherichia coli is inhibited atahoo.com (H. Abu Ali).
k.
served.high concentrations of zinc(II). However, low concentrations of
zinc(II) have a promoting action on the growth of E. coli [6]. Zinc
also can inhibit the growth of Streptococcus faecalis, Klebsiella
pneumoniae, Staphylococcus aureus and some soil bacteria [7]. Many
anti-bacterial drugs when chelated to the metal, show altered
bioability and sometimes the chelated drug is more effective than
the free ligand [8]. This is due to the chelation of a bulky ligand to a
metal cationwhich reduces the polarity of the ion and increases the
lipophilicity of the metal complex, which can result in increased
damage to bacterial cell walls and prohibit the transfer of zinc into
the cell [9].
Malaria is one of the most prevalent parasitic diseases in the
world. It is caused by different species of Plasmodium, Plasmodium
vivax, Plasmodium falciparum, Plasmodium malariae and Plasmo-
dium ovale of which P. ﬂaciparum is the most virulent human ma-
laria parasite. The parasite lives within human red blood cells and
consumes over two thirds of the hemoglobin of the host cell.
H. Abu Ali et al. / European Journal of Medicinal Chemistry 89 (2015) 67e7668Digestion of hemoglobin by malaria parasite leads to the contin-
uous liberation of free heme (Iron protoporphyrin IX) along with
oxygen, causing formation of a ferric form of heme called ferri-
protoporphyrin IX. This heme can lead to the killing of the para-
sitewhich has evolved a unique detoxiﬁcationmethod of free heme
through its conversion into a non-toxic, inert, insoluble, crystalline
and black-brown pigment called homozoin [10e14]. b-Hematin
crystals (Hemazoin) are made of dimer of hematin molecules that
are oxygen coordinate bond links the central iron of one hematin to
the oxygen of the carboxylate side-chain of the adjacent hematin
[15]. Many clinically used antimalarial drugs such as chloroquine,
amodaquine; meﬂoquine and 4-aminoquinoline are thought to act
by inhibiting the formation of hemozoin in the food vacuole. This
prevents the detoxiﬁcation of the heme released in this compart-
ment, and kills the parasite [16]. Chloroquine, a quinoline-ring
drug, is widely used for malaria treatment. However, resistance to
chloroquine has increased owing to extensive and uncontrolled use
[17,18]. Chloroquine resistance is considered as major universal
challenging problem and the need of new effective anti-malarial
drugs is an urge. In this research both a semi-quantitative [19]
and a quantitative screening methods for a new potential antima-
larial drugs were used [20,21]. Naproxen [(þ)-6-methoxy-a-
methyl-2-naphthalene acetic acid], Fig. 1 is a non-steroidal drug
with antipyretic, anti-inﬂammatory and analgesic properties
[22e24]. In addition, naproxen is used to relieve fever, pain and
symptoms of arthritis, gout, bursitis and menstrual cramping. It
acts as cyclooxygenase inhibitor that interferes with the COX-1 and
COX-2 forms of that enzyme [25]. Some anti-inﬂammatory drugs
are sodium salts of carboxylic acids; the Na metal can be replaced
by transitionmetals to improve some of these drugs characteristics.
Metal ion complexation with naproxen increases the transport of
naproxen into the cells as supported by the fact that the transport of
organic ligands into cells can be facilitated by the formation of
metal complexes [24,26].
Zinc complexes of aliphatic carboxylates such as formate, ace-
tate, propionate and butyrate and aromatic carboxylates such as
benzoate, 2-bromobenzoate 5-chlorosalicylate, 4-chlorosalicylate
and salicylate with nitrogen based ligands have been synthesized
and screened as bio-active compounds [1,6,27e38]. Zn(naproxen)2
complex have been synthesized and characterized by IR, NMR and
their anti-inﬂammatory studies were performed [24]. The in-
teractions of this drug have been studied widely for copper with
biologically active N-donor ligands such as 2,2-bipyridine, 1,10-
phenanthroline and pyridine [22]. Other metal complexes of nap-
roxen such as; the cobalt(II) complexes with naproxen in the
presence of nitrogenedonor heterocyclic ligands (1,10-
phenanthroline, 2,2-bipyridine and pyridine) have been synthe-
sized and characterized with physiochemical and spectroscopic
techniques [39]. The ligands 1,10-phenanthroline, 2,9-dimethyl-
1,10-phenanthroline, 2-aminopyridine, imidazole and their de-
rivatives, as well as many of their complexes, are exhibiting anti-
bacterial [40e46], anti-viral [47,48], and anti-malarial [49,50],
anti-fungal [51] and anti-tumor activities [49,52,53] depending on
the nature of the ligand and the type of the metal ion. In this work,
synthesis, characterization, antibacterial and antimalarial activity
of novel mixed ligand complexes of Zn(II) naproxen with nitrogen
based ligands i.e, 2,9-dimethyl-1,10-phenanthroline, 1,10-C
CH3O
CH3
COOH
H
Fig. 1. Structural formula of D-naproxen.phenanthroline, 2-aminopyridine, imidazole and 1,2-dimethyl
imidazole are reported. The crystal structure of complex 3 which
showed a promised antimalarial activity was also determined.
2. Results and discussion
2.1. Synthesis of zinc complexes
[Zinc naproxen complex] (1) was prepared by reacting 1 eq of
zinc chloride with 2 eq of sodium naproxen in water Scheme 1. The
desired product was obtained as a white solid. Five mixed ligand
zinc naproxen compounds have been prepared by the reaction of
1:2 molar ratio of complex (1) with the nitrogen donor ligands in
acetone with stirring at ambient conditions Scheme 2. The physical
properties of 1e6 are summarized in Table S1 (Appendix A.
Supplementary Materials).
2.2. X-ray crystallographic study of complex 3
Suitable crystals for complex 3 were obtained by recrystalliza-
tion from 1:1 mixture acetonitrile/chloroform and X-ray crystallo-
graphic analysis was determined. The crystal structure of complex 3
with the atomic labeling is illustrated in Fig. 2 and a summary of
selected bond lengths and bond angles are given in Table S2.
Complex 3 crystallized in themonoclinic space group P2(1) with
four molecules in the unit cell and one acetonitrile molecule per
each complex molecule. Two crystallographically inequivalent
molecules of [Zn(nap)22,9-dmphen] exist in the asymmetrical unit,
these two units are contacted by p…p interaction between the ar-
omatic group of naproxen in one molecule and the 2,9-dmphen of
the other Fig. 3.
In the ﬁrst asymmetrical molecule, zinc has a distorted tetrahe-
dral ZnO2N2 chromophore; the Zn1 atom is coordinated to two
monodentate oxygen atoms from naproxen ligands with Zn1eO1
andZn1eO4distances equal to 1.960 and1.927Å, respectively, this is
in agreement with ZneO bond distances in reported monodentate
zinc benzoate complexes, zinc nitro benzoate complexes and 4-
hydroxy benzoate complexes (1.96e2.20 Å) [54e56]. On the other
hand, Zn1eO2 and Zn1eO5 non-bonded contacts are 2.927 and
2.792 Å, respectively. Bond angles around zinc are in agreementwith
tetrahedral angles (Table S2) with slight deviation that arises from
the rigidity of the ﬁve-member ring that formwith 2,9-dmphen.
In the second asymmetrical molecule of [Zn(nap)22,9-dmphen]
with ZnO3N2 chromophore, using the geometrical parameter t
(t ¼ (b  a)/60, where b and a are the largest angles around the
central atom) deﬁned by Addison et al. [57]; the analysis of this
complex gives a value of 0.11 which suggest a distorted square
pyramidal arrangement around Zn(II) atom. Here one of the nap-
roxen coordinated in asymmetrical chelating bidentate coordina-
tion with Zn2eO7 and Zn2eO8 distances equal to 2.241 and
2.141 Å, respectively. The other naproxen is coordinated in mono-
dentate mode, Zn2eO10 ¼ 1.921 Å, and Zn2eO11 non-bonded
contacts ¼ 2.997 Å. The distorted tetragonal base plane is deﬁned
by the atoms O8, N4, N3 and O7. Deviation from regular tetragonal
geometry is apparent from the observed binding angles, {N(3)e
Zn(2)eO(8) ¼ 91.39, N(3)eZn(2)eO(7) ¼ 137.59, N(4)eZn(2)e
O(7) ¼ 97.05, N(4)eZn(2)eO(8) ¼ 130.98, O(7)eZn(2)e
O(8) ¼ 58.24} and the axial position are occupied by the O10.
However, bond distances and angles within 2,9-dmphen and nap-
roxen gave the expected values for such complexes.
2.3. Infrared and UVeVis spectra
Infrared spectral data of zinc naproxen complexes 1e6 in the
400e4000 cm1 range as KBr disk are summarized in Tables S3eS6
ZnCl2 +
H2O [Zinc naproxen complex]
1
2
O
NaO O
Scheme 1. Synthesis of complex 1.
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sodiumsalts of naproxen and complex 1 are comparedwith previous
literature data [24,26,58e60]. The asymmetric and symmetric
y(COO) stretching vibrations for sodium naproxen have been
observed at 1540 and 1385 cm1, respectively, and the separation
between them is Dy(COO) ¼ 155 cm1. In complex 1, yas(COO)
shifts to 1600 cm1 and ys(COO) to 1390 cm1 and
Dy(COO) ¼ 210 cm1 which is higher than Dy(COO) of sodium
naproxen [61]. Complex 1 may coordinated as a monodentate mode
since [Dn(COO)1 (210 cm1)>>Dn(COO)Na(nap) (155 cm1)] [62,63].
In accordance with literature data yZneO stretching vibrations for
complexes 1e6were found in the 412e578 cm1 range [26,56].
The Dy(COO) for complexes 2, 3, 4, 5 and 6 were 215, 230, 216,
196 and 229 cm1, respectively. This suggest monodentatelycoordinated carboxylate groups to the zinc atom (See Scheme 2),
since Dy(COO) of these complexes is higher than Dy (COO)
Na(nap) (155 cm1) [64]. However, crystal structure of complex 3
showed three monodentate and one bidentate naproxen groups
(See Fig. 2).
In the spectrum of complex 4 two bands were observed at 3335
and 3211 cm1 which are attributed to the primary NH2 group,
yas(NeH) and ys(NeH), respectively. Compared to the NH2
stretching frequencies of 2-ampy ligand [nas(NeH) ¼ 3447 and
ns(NeH)¼ 3171 cm1], considerable shift caused by coordination to
zinc was noticed.
In the IR spectrum of complex 6 showed one broad band at
3127 cm1 which is attributed to the secondary NH bond stretching
in the pyrimidine ring. Compared to the NH stretching frequencies
Fig. 2. View of the molecular structure of 3 showing the atom labeling scheme.
Fig. 3. pep interactions of molecule 3.
H. Abu Ali et al. / European Journal of Medicinal Chemistry 89 (2015) 67e7670of imidazole ligand (3125 cm1), a shift caused by coordination to
zinc was also noticed. The IR frequencies of all zinc complexes, 2e6
were compared with their parent ligands and other zinc complexes
[65e69].
UVeVisible absorption of all zinc complexes, 1e6 in the
200e700 nm range were carried out and compared with their
parent ligands in which only small shift caused by coordination to
zinc was observed Table 1.Table 1
UVeVis data of complexes 1e6.
Complex lmax (nm) εmax (L mol1 cm1)
1 264, 274, 333 962, 923, 270
2 233, 271, 292, 318, 333 17903, 4902, 1349, 419, 455
3 274, 298, 319, 333 3400,1531,571,560
4 265, 275, 320, 333 1418, 1626, 520, 500
5 264, 274, 320, 334 1064, 1148, 470, 491
6 264, 274, 320, 335 632, 705, 350, 400The absorption bands of these metal complexes (in the
200e350 nm range) may be attributed to pep* and nep* transi-
tions, however, metal to ligand charge transfer transitionmay occur
in this range although it was difﬁcult to assign any of them due to
overlap with ligand transitions. Moreover, the d orbital in the zin-
c(II) atom is completely ﬁlled; so no ded transition bands have been
detected in all zinc complexes.2.4. 1H NMR and 13C{1H} NMR results
The 1H and 13C{1H} NMR spectral data for 1e6, naproxen and the
parent N-donor ligands are reported in Tables S6eS11 (Appendix A.
Supplementary Materials). The results are in agreement with the
proposed structures as shown in Scheme 2. The 1H NMR and 13C
{1H} chemical shifts of naproxen and the N-donor ligands were
found in the expected positions of free ligands with a shift due to
the coordinationwith metal. The value of d 13C chemical shift of the
(CH3) of naproxen for 1e6 and the free naproxen are summarized in
Table 2
13C{1H} NMR spectral data of the CH3 carbon of
naproxen for 1e6.a
Compound d (CH3)
1 19.59
2 19.58
3 19.75
4 19.60
5 20.36
6 20.36
Naproxen 19.07
a ppm downﬁeld relative to TMS as internal
standard (CDCl3).
H. Abu Ali et al. / European Journal of Medicinal Chemistry 89 (2015) 67e76 71Table 2. This carbon is chosen for comparison because it is close to
the coordination site (COO) on one hand; and it is less affected by
other external conditions on the other hand. This carbon exhibited
downﬁeld chemical shift in the range of 0.51e1.29 ppm compared
to the free naproxen ligand value; which resulted from complex
formation. The integration ratios of the 1H NMR signals of 2e6 are
in agreement with the proposed structure as shown in Scheme 2.
The proposed structures were also determined by comparisonwith
similar published data [22].
2.5. In vitro anti-bacterial activity results
The solution stability of the complexes were checked by
repeated 1H and 13C{1H} NMR measurements in DMSO and CDCl3
solvents and they proved high solution stability. Zinc naproxen
complexes 1e6 were tested for their anti-bacterial activity against
Gþ bacteria (Staphylococcus aureus and Micrococcus luteus) and G-
bacteria (Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas
aeruginosa and Escherichia coli). The anti-bacterial screening data
were summarized in Table 3 using DMSO as a negative control
while Erythromycin and Gentamycin used as positive controls.
Sodium naproxen and Zn(II) as chloride did not show any signiﬁ-
cant activity at the same concentration, but Erythromycin as posi-
tive control showed high anti-bacterial activity against all tested
bacterial species (except P. aeruginosa) with inhibition zone
17e43 mm, Gentamycin as positive control showed high anti-
bacterial activity against all tested bacterial species with inhibi-
tion zone of 23e33 mm.
Complex 1 showed low anti-bacterial activity with inhibition
zone 8e10 mm for P. mirabilis, E. coli and K. pneumoniae. Complex 2
showed high anti-bacterial activity against all tested bacterial
species with inhibition zone 16e21 mm. Although complex 3
showed high anti-bacterial activity against Gþ-bacterial with inhi-
bition zone around 20 mm, it showed low anti-bacterial activity
against G-bacteria with inhibition zone 7.7e11 mm. Complex 4
showed intermediate anti-bacterial activity only against Gþ-bac-
teria with inhibition zone around 12 mm. Complexes 5 and 6Table 3
Anti-bacterial activity data of complexes 1e6 in (mm)/8.5 mmol/L.
Complex Gþ bacteria G bacte
M. luteus S. aureus P. aerugin
(1) e e e
(2) 16.0 ± 2.1 16.0 ± 1.1 19.0 ± 1.
(3) 20.0 ± 1.5 20.0 ± 1.0 e
(4) 12.3 ± 1.2 12.3 ± 0.6 e
(5) e e e
(6) 8.7 ± 0.6 8.3 ± 1.2 e
Naproxen e e e
ZnCl2 e e e
Erythromycin 39.0 43.0 e
Gentamycin 33.0 27.0 23.0showed low anti-bacterial activity against E. coli and K. pneumonia
(with inhibition zone around 9.7 mm) and S. aureus and M. luteus
(with inhibition zone around 8.5 mm), respectively. Due to their
higher anti-bacterial activity, complexes 2, 3 and 4 were compared
with their parent nitrogen donor ligands against all tested bacterial
species to determine the effect of the complexation on anti-
bacterial activity. Different dilutions of these complexes and their
parent ligands in DMSO in the concentration range
8.50e2.12 mmol/L were prepared using the same procedure. In this
part the complexes and their parent ligands were tested in the
same plate and in the same conditions to determine the MIC. The
anti-bacterial results were summarized in Table 4.
The results presented in Table 4 showed that the anti-bacterial
activity of 1,10-phenanthroline ligand showed higher anti-
bacterial activity than complex 2 against all tested bacterial spe-
cies (except P. aeruginosa) where the complexation of the ligand
1,10-phenanthroline with zinc naproxen decreased the anti-
bacterial activity. In the case of P. aeruginosa, complex 2 exhibit
very good activity and notably higher than the parent ligands.
Complex 2 was the only structure which showed anti-bacterial
activity against P. aeruginosa.
Complex 3 showed higher anti-bacterial activity against Gþ-
bacteria than G-bacteria. Also this complex showed higher anti-
bacterial activity against G-bacteria compared to 2,9-dimethyl-
1,10-phenanthroline ligand. On the other hand, the activity of
complex 2 and the parent ligand are similar against the Gþ-bacte-
ria. This difference could be explained by the different cell wall
structure of Gþ-bacteria and G-bacteria. It is possible that the
enhancement of lipophilicity of complex 2 plays a role in the
increased activity against G-bacteria.
Complex 4 showed anti-bacterial activities only against Gþ
bacteria. 2-Aminopyridine ligand did not show anti-bacterial ac-
tivity against all tested bacterial species. The complexation of the
ligand 2-aminopyridine with zinc naproxen increased the anti-
bacterial activity against Gþ bacteria.2.6. Anti-malarial activity
2.6.1. Semi-quantitative method
Two different zinc naproxen complexes 2 and 3, and their parent
phenanthroline derivative ligands were all evaluated for their
inhibitory effect on in-vitro beta-hematin formation. Results of the
semi-quantitative method are shown in Fig. 4 and Fig. 5 (complexes
1, 2, 4, 5 and 6 did not show any signiﬁcant inhibitory effect on in-
vitro beta-hematin formation; complex 2was used as a comparison
on Fig. 3 because of the similarity in structure with the active
complex 3).
As shown in Fig. 4, complex 3 with an absorbance value of 0.04
(at a concentration of 1 mg/ml) was the only one of these four
compounds with a potential anti-malarial activity when comparedria
osa E. coli K. pneumoniae P. mirabilis
10.0 ± 1.0 10.0 ± 1.0 8.0 ± 0.6
1 20.0 ± 2.1 20.0 ± 2.5 21.0 ± 1.0
7.7 ± 1.2 11.0 ± 1.2 e
e e e
9.7 ± 0.6 9.7 ± 0.6 e
e e e
e e e
e e e
18.0 21.0 17.0
28.0 32.0 28.0
Table 4
In-vitro anti-bacterial activity data at different concentrations and the MIC values of complexes 2, 3, 4 and their parent ligands.
M. luteus S. aureus P. aeruginosa E. coli K. pneumoniae P. mirabilis
Diameter of inhibition zone of Complex (2) (mm)
8.50 mmol/L 16.0 16.0 19.0 20.0 20.0 21.0
4.25 mmol/L 13.0 14.0 14.0 16.0 17.0 16.0
2.12 mmol/L 9.0 10.0 12.0 14.0 14.0 14.0
MIC (mmol/L) 2.12 1.06 2.12 0.265 1.06 1.06
Diameter of inhibition zone of 1,10-phenanthroline ligand (mm)
8.50 mmol/L 29.0 30.0 8.0 27.0 25.0 30.0
4.25 mmol/L 25.0 24.0 7.0 23.0 20.0 24.0
2.12 mmol/L 17.0 17.0 e 18.0 15.0 17.0
MIC (mmol/L) 0.531 1.06 4.25 0.531 0.531 0.531
Diameter of inhibition zone of Complex (3) (mm)
8.50 mmol/L 20.0 20.0 e 7.7 11.0 e
4.25 mmol/L 18.0 18.0 e 7.7 11.0 e
2.12 mmol/L 17.0 16.0 e 7.0 10.0 e
MIC (mmol/L) 0.531 0.265 >8.50 1.06 0.265 >8.50
Diameter of inhibition zone of 2,9-dimethyl-1,10-phenanthroline ligand (mm)
8.50 mmol/L 21.0 24.0 e e 8.0 e
4.25 mmol/L 19.0 21.0 e e 7.0 e
2.12 mmol/L 12.0 19.0 e e e e
MIC (mmol/L) 2.12 0.265 >8.50 >8.50 4.25 >8.50
Diameter of inhibition zone of Complex (4)a (mm)
8.50 mmol/L 12.0 12.0 e e e e
4.25 mmol/L 10.0 10.0 e e e e
2.12 mmol/L 9.0 8.0 e e e e
MIC (mmol/L) 0.531 1.06 >8.50 >8.50 >8.50 >8.50
a The parent ligand of this complex 2-aminopyridine did not show any biological activity on this concentration range.
H. Abu Ali et al. / European Journal of Medicinal Chemistry 89 (2015) 67e7672to the standard drugs (at a concentration of 0.1 mg/ml). The efﬁ-
ciency of the drug used is inversely proportional to the absorption,
low absorption indicates higher efﬁciency and vice versa. It is
important to mention that each result is the average of 26 indi-
vidual experiments. It is obvious that complex 3 needs more
investigation and the test was repeated using lower concentrations
of this complex. Different dilutions of complex 3 were made and
the results are summarized in Fig. 5. Complex 3 with the range of
concentrations between 1 and 0.6 mg/ml showed a good inhibition
activity on the formation of b-hematin, also no inhibition was
noticed at 0.5 mg/ml.2.6.2. Quantitative method
According to method of use, the result of complex compared to
DMSO (as negative control) and Amodiaquine (AQ as positiveFig. 4. Column diagram representing Semi-Quantitative test results of potential anti-mala
(compound 3): 2,9 dimethyl-1,10-phenanthroline, (complex 2): Zn(nap)21,10-phen and (c
compared to Chloroquine (CQ) Amodiaquine (AQ) and 2-mercaptopyramidine (2-MP) as p
inversely proportional to drugs efﬁciency, the lower the absorption is, the drug is considercontrol) in terms of b-hematin formation is shown in Fig. 6. Com-
parison in terms of drug efﬁciency is seen in Fig. 7.
Fig. 6 represents the percentage yield of b-hematin formation.
Interestingly, the percentage yield of b-hematin formation in the
presence of complex 3 was 25% and that of AQ was 7.5%, both at
concentration 0.4 mM comparing to the negative control which
was 87.5%.
Comparison in terms of efﬁciency of the complex under inves-
tigation as anti-malarial drug is shown in Fig. 7. It is obvious that
complex 3 has a considerable anti-malarial activity in inhibiting b-
hematin formation with efﬁciency 75%, when compared to AQ
92.5%, and DMSO 12.5%.
This inhibition activity of b-hematin may be due to the in-
teractions between complex 3 and ferri-heme; which inhibited the
formation of b-hematin in vitro. Forces involved in stability of this
interactions may involve pep stacking forces of therial drugs, (compound 1): Zn naproxen complex, (compound 2): 1,10-phenanthroline,
omplex 3): Zn(nap)2-2,9 dmphen, all at concentration 1 mg/ml dissolved in DMSO,
ositive controls, while water and DMSO were used as negative controls, absorption is
ed to be more efﬁcient.
Fig. 5. Column diagram representing the semi-quantitative test results of potential anti-malarial drug Zn(nap)2-2,9-dimethyl-1,10 phenanthroline (3) dissolved in DMSO, compared
to Chloroquine, Amidoquine and 2-Mercaptopyrimidine as positive controls, while water and DMSO used as negative controls, showing the absorption values of dissolved b-
hematin (alkaline hematin) at 405 nm using ELISA reader, absorption is inversely proportional to drugs efﬁciency, the lower the absorption is, the drug is considered to be more
efﬁcient.
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action between naproxen oxygen atoms and propanoic acid of the
ferri-heme and coordination bond between zinc(II) and the N-
donor groups of the heme [70].
Complex (2) (see Fig. 3) did not show any considerable activity
although it is similar to complex 3. These two complexes are only
different in the methyl groups in the 1 and 9 positions of the
phenanthroline in complex 3. The additional methyl groups of the
2,9-dimethyl-1,10-phenanthroline may form electrostatic interac-
tion with ferri-heme may be play a major rule in stabilizing the
interaction with ferri-heme. The mechanism of inhibition is
thought to be through the formation of a complex between com-
plex 3 and ferriheme which prevent the formation of b-hematin.3. Experimental
3.1. Instruments
Infrared (IR) absorption spectra were recorded using a Varian
600 FT-IR spectrometer in the region of 400e4000 cm1 using KBr
pellet technique. 1H and 13C{1H} NMR spectra were recorded in
CDCl3 and DMSO (d6) as solvents with a Varian Unity spectrometer
(300 and 75 Hz) for 1H and 13C{1H} nucleus, respectively. UVeVis
measurements were recorded on a Hewlett Packard 8453 photo
diode-array spectrometer in the 200e800 nm region using DMSO,
CHCl3, and CH3OH as solvents. Melting points were determined in
capillary tube with EZ-melt apparatus and are uncorrected.Fig. 6. Column diagram representing the percentage yields of complex: Zn(nap)2-2,9-
dmphen (3) as potential anti-malarial drug, compared to Amidoquine and DMSO at
0.4 mM. Yields are inversely proportional to drugs efﬁciency, the lower the yield is, the
drug is considered to be more efﬁcient.3.2. Materials
The starting materials used in the present work were purchased
from SigmaeAldrich with high purity and were used without
further puriﬁcation. Solventswere also purchased from commercial
sources. Pure cultures ofM. luteus, S. aureus, P. aeruginosa, E. coli, K.
pneumoniae and P. mirabilis were obtained from the Biology and
Biochemistry Department at Birzeit University.3.3. Synthesis
3.3.1. Synthesis of [zinc naproxen complex] (1)
Zinc naproxen complex was prepared by reacting 1 eq of zinc
chloride with 2 eq of sodium naproxen in 70 ml H2O solvent at
room temperature. The complex thus formed was ﬁltered, washed
with water and air dried. Zinc naproxen was also previously pre-
pared as shown in the literature [24e26].The complex is soluble in
acetone, dichloromethane, methanol, ethanol and acetonitrile. (1):
(86%) yield, m.p. (228e233) C; 1H NMR (CDCl3): d ¼ 1.39 (d, 3H,
CH3), 3.70 (bs, 1H, CH), 3.90 (s, 3H, OCH3), 7.00 (bs, 1H, CH), 7.08 (d,
1H, CH, 3J ¼ 8.4 Hz), 7.42 (bs, 1H, CH), 7.54 (s, 1H, CH), 7.58 (d, 1H,
CH), 7.61 (d, 1H, CH); 13C{1H} NMR (CDCl3): d ¼ 19.59 (CH3), 48.37
(CHeCH3), 55.44 (OeCH3), 105.70 (CH), 118.82 (CH), 125.88 (CH),
126.87 (CH),127.17 (CH),129.26 (CH),133.51 (CH),157.44 (CeOCH3),
181 (C]O); IR (cm1, KBr): 3080, 2955, 1696, 1630, 1600, 1485,
1455, 1390,1370,1260, 1210,1160, 1027, 974, 927, 811, 744, 615, 591;
UVeVis, (CHCl3), l (nm): 264, 274, 333.Fig. 7. Column diagram representing the efﬁciencies of potential anti-malarial drug,
Zn(nap)2-2,9-dmphen (3), compared to Amidoquine, all at a concentration of 0.4 mM.
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1,10-Phenanthroline (0.45 g, 2.3 mmol) was dissolved in 30 ml
acetone and added drop-wise to a stirred acetone solution of (1)
(0.6 g, 1.1 mmol). The solution was stirred for 2 h and a white solid
was formedwhich was then ﬁltered and air dried. The compound is
soluble in dichloromethane and methanol.
[Zn(nap)21,10-phen] (2): (80%) yield, m.p. (220e230) C; 1H
NMR (CDCl3): d¼ 1.52 (d, 3H, CH3, 3JHeH ¼ 6.9 Hz), 3.87 (bs, 4H, CH,
OCH3), 7.02 (d,1H, CH, 3JHeH¼ 3 Hz), 7.06 (d,1H, CH, 3JHeH¼ 1.5 Hz),
7.40 (d, 2H, CH, 3JHeH¼ 8.1 Hz), 7.49 (d, 1H, CH, 3JHeH¼ 8.7 Hz), 7.52
(d, 2H, 2CH), 7.60 (bs, 2H, CHPhen), 7.68 (t, 2H, CHPhen,
3JHeH ¼ 7.8 Hz), 7.81 (bs, 2H, CHPhen), 8.53 (d, 2H, CHPhen); 13C{1H}
NMR (CDCl3): d ¼ 19.58 (CH3), 46.67 (CHeCH3), 55.49 (OeCH3),
105.69 (CH),118.59 (CH),120.96 (2CHPhen),125.86 (CH),126.74 (CH),
127.34 (CH), 129.12 (CH), 129.44 (2CHPhen), 133.48 (CH), 138.68
(2CHPhen), 139.91 (2CHPhen), 149.64 (2CHPhen), 157.38 (CeOCH3),
(C]O) was undetectable; IR (cm1, KBr): 3058, 2969, 2931, 2837,
1603, 1522, 1483, 1458, 1430, 1388, 1262, 1159, 1121, 1061, 1029, 960,
927, 852, 824, 777, 726, 697, 543, 475, 429; UVeVis, (MeOH), l (nm):
233, 271, 292, 319, 333.3.3.3. Synthesis of [Zn(nap)22,9-dmphen] (3)
Same procedure was followed as in complex 2 except with 2,9-
Dimethyl-1,10-phenanthroline (0.49 g, 2.3 mmol) and complex (1)
(0.67 g, 1.15 mmol). Suitable crystals for X-ray structural analysis
were obtained by recrystallization from 1:1 mixture of acetonitrile
and chloroform. The compound is soluble in chloroform, acetoni-
trile and acetone.
[Zn(nap)22,9-dmphen] (3): (72%) yield, m.p. (209e213) C; 1H
NMR (CDCl3): d ¼ 1.49 (d, 3H, CH3, 3JHeH ¼ 7.2 Hz), 2.74 (s, 6H,
CH3Phen), 3.86 (q, 1H, CH), 3.89 (s, 3H, OCH3), 7.03 (bs, 1H, CH), 7.06
(d, 1H, CH, 3JHeH ¼ 2.7 Hz), 7.40 (d, 2H, CHPhen, 3JHeH ¼ 2.7 Hz), 7.43
(d, 1H, CH), 7.51 (d, 2H, CHnap, 3JHeH¼ 8.7 Hz), 7.59 (bs, 1H, CH), 7.69
(d, 2H, CHPhen, 3JHeH ¼ 3.9 Hz), 8.17 (d, 2H, CHPhen, 3JHeH ¼ 8.4 Hz);
13C{1H} NMR (CDCl3): d ¼ 19.75 (CH3), 24.81 (2CH3Phen), 47.06
(CHeCH3), 55.48 (OeCH3), 105.70 (CH), 118.49 (CH), 125.70
(2CHPhen), 125.81 (CH), 126.36 (2CHPhen), 126.61 (CH), 127.12 (CH),
127.39 (2Cphen), 129.29 (CH), 132.12 (2CHPhen), 133.40 (CH), 139.11
(2CHPhen), 157.29 (CeOCH3), 160.76 (2CHPhen), 181.87 (C]O); IR
(cm1, KBr): 3056, 2964, 2930, 1605, 1505, 1453, 1375, 1270, 1212,
1156, 1121, 1033, 927, 852, 813, 782, 750, 683, 661, 549, 475, 416;
UVeVis, (DMSO), l (nm): 274, 298, 319, 333.3.3.4. Synthesis of [Zn(nap)2(2-ampy)2] (4)
2-Aminopyridine (0.18 g, 1.9 mmol) was dissolved in 30 ml
acetone and added drop-wise to a stirred acetone solution of (1)
(0.50 g, 0.96 mmol). The solution was stirred for 2 h and then was
evaporated under vacuum, washed with ether to afford an oily
product which was dried under vacuum. The compound is soluble
in chloroform, dichloromethane, acetonitrile, ethanol and acetone.
[Zn(nap)2(2-ampy)2] (4): (80%) yield, m.p. (74e80) C; 1H NMR
(CDCl3): d ¼ 1.52 (d, 3H, CH3, 3JHeH ¼ 6.9 Hz), 3.86 (q, 1H, CH), 3.88
(s, 3H, OCH3), 5.71 (bs, 2H, NH2), 6.23 (t, 1H, CHpy, 3JHeH ¼ 6.3 Hz),
7.04 (bs, 1H, CH), 7.07 (d, 1H, CH, 3JHeH ¼ 2.1 Hz), 7.18 (t, 1H, CHpy,
3JHeH ¼ 6.9 Hz), 7.42 (d, 1H, CH), 7.45 (d, 1H, CHPy), 7.55 (d, 1H, CH,
3JHeH ¼ 7.8 Hz), 7.58 (d, 1H, CH, 3JHeH ¼ 3.9 Hz), 7.59 (d, 1H, CHpy,
3JHeH ¼ 5.1 Hz), 7.64 (s, 1H, CH); 13C{1H} NMR (CDCl3): d ¼ 19.60
(CH3), 47.53 (CHeCH3), 55.50 (OeCH3), 105.75 (CH), 111.36 (CHpy),
113.00 (CHpy), 118.66 (CH), 125.96 (CH), 126.80 (CH), 127.36 (CH),
129.34 (CH), 139.23 (CHpy), 146.17 (CHpy), 157.40 (CeOCH3), 159.19
(CeNH2 py), 181.52 (C]O); IR (cm1, KBr): 3335, 3211, 3056, 2970,
2933, 1605, 1501, 1452, 1389, 1358, 1267, 1212, 1160, 1120, 1063,
1031, 960, 927, 853, 812, 771, 691, 522, 475, 417; UVeVis, (CHCl3), l
(nm): 265, 275, 320, 333.3.3.5. Synthesis of [Zn(nap)2(imid)2] (5)
Same procedure was followed as in complex 2 except with
imidazole (0.26 g, 3.8 mmol) and complex (1) (1.0 g, 1.9 mmol). The
compound is soluble in chloroform and DMSO.
[Zn(nap)2(imid)2] (5): (78%) yield, m.p. (152e155) C; 1H NMR
(DMSO-d6): d ¼ 1.44 (d, 3H, CH3, 3JHeH ¼ 6.9 Hz), 3.74 (q, 1H, CH,
3JHeH ¼ 6.9 Hz), 3.83 (s, 3H, OCH3), 7.10 (d, 1H, CH, 3JHeH ¼ 8.4 Hz
and 2H, CHImid), 7.23 (s, 1H, CH), 7.46 (d, 1H, CH, 3JHeH ¼ 8.7 Hz),
7.69 (bs, 2H, 2CH and CHImid), 7.71 (d, 1H, CH, 3JHeH ¼ 12 Hz), 8.02
(bs, 1H, NHImid); 13C{1H} NMR (DMSO-d6): d ¼ 20.36 (CH3), 47.04
(CHeCH3), 55.76 (OeCH3), 106.32 (CH), 119.08 (CH), 125.97 (CH),
127.13 (CH), 127.54 (CH), 129.15 (CH), 129.69 (CHImid), 133.63 (CH),
139.32 (CHImid), 157.51 (CeOCH3), 178.93 (C]O); IR (cm1, KBr):
3127, 3055, 2935, 2865, 1608, 1586, 1503, 1452, 1390, 1342, 1265,
1208, 1160, 1072, 1027, 956, 927, 857, 814, 760, 692, 624, 534, 473,
413; UVeVis, (CHCl3), l (nm): 264, 274, 320, 334.
3.3.6. Synthesis of [Zn(nap)2(1,2-dmimid)2] (6)
Same procedure was followed as in complex 2 except with 1,2-
dimethyl imidazole (0.2 ml, 2.3 mmol) and complex (1) (0.6 g,
1.15 mmol). The compound is soluble in chloroform, dichloro-
methane, ethanol and acetonitrile.
[Zn(nap)2(1,2-dmimid)2](6): (83%) yield, m.p. (132e136) C; 1H
NMR (CDCl3): d ¼ 1.50 (d, 3H, CH3, 3JHeH ¼ 7.2 Hz), 2.01 (s, 3H,
CH3Imid), 3.23 (s, 3H, CH3Imid), 3.83 (q, 1H, CH), 3.87 (s, 3H, OCH3),
6.53 (bs, 1H, CHImid), 6.83 (bs, 1H, CHImid), 7.03 (s, 1H, CH), 7.05 (d,
1H, CH, 3JHeH ¼ 2.4 Hz), 7.49 (d, 1H, CH), 7.51 (d, 1H, CH,
3JHeH ¼ 6 Hz), 7.56 (d, 1H, CH, 3JHeH ¼ 9.3 Hz), 7.65 (s, 1H, CH); 13C
{1H} NMR (CDCl3): d ¼ 11.70 (CH3Imid), 19.83 (CH3), 33.21
(NeCH3Imid), 47.83 (CHeCH3), 55.49 (OeCH3), 105.66 (CH), 118.33
(CH), 120.37 (CHImid), 125.84 (CH), 126.35 (CH), 127.74 (CH), 129.17
(CH), 129.45 (CHImid), 133.28 (CH), 146.67 (CImid), 157.20 (CeOCH3),
180.54 (C]O); IR (cm1, KBr): 3118, 3056, 2966, 2932, 1605, 1505,
1461, 1418, 1376, 1341, 1265, 1212, 1157, 1119, 1093, 1062, 1029, 958,
926, 854, 824, 776, 747, 674, 652, 553, 479, 445; UVeVis, (CHCl3), l
(nm): 264, 274, 320, 335.
3.4. X-ray crystallography
X-ray intensities data of complex 3 was carried out at room
temperature on a Bruker SMART APEX CCD X-ray diffractometer
system (graphiteemonochromated Mo Ka radiation l ¼ 0.71073 Å)
by using the SMART software package [71]. The data were reduced
and integrated by the SAINT program package [72]. The structure
was solved and reﬁned by the SHELXTL software package [73]. H
atoms were located geometrically and treated with a riding model.
Crystal data and details of the data collection and reﬁnement are
summarized in Table 5.
3.5. Anti-bacterial activity
Zn(II) naproxen complexes (1e6) were screened for their anti-
bacterial activity against Gþ-bacteria (S. aureus and M. luteus) and
G-bacteria (K. pneumoniae, P. mirabilis, P. aeruginosa and E. coli).
These complexes were tested in vitro using the agar well diffusion
method [74]. Single bacteria colonies were dissolved in sterile sa-
line to obtain suspended cells with turbidity equivalent to a MC
Farland 0.5 standard. The bacterial inocula were spread on the
surface of the nutrient agar with the help of a sterile cotton swab,
then 6 mm diameters wells were dug in agar medium using sterile
glassy borer.
The Zinc(II) complexes were prepared in DMSO (8.5 mmol/L)
and were introduced into the respective wells using 50 mL pipette,
one of the wells was supplemented with DMSO as control. These
plates were placed in a 37 C incubator for 24 h to allow bacterial
Table 5
Crystal data and structure reﬁnement for [Zn(nap)22,9-dimethyl-1,10-
phenanthroline] (3).
Empirical formula C44 H41N3 O6 Zn
Formula weight 773.17
Temperature 173(1) K
Wavelength 0.71073 Å
Crystal system Monoclinic
Space group P2(1)
Unit cell dimensions a ¼ 15.0063(9) Å a ¼ 90 .
b ¼ 14.1711(8) Å b ¼ 91.705(1) .
c ¼ 17.796(1) Å g ¼ 90 .
Volume 3782.7(4) Å3
Z 4
Density (calculated) 1.358 Mg/m3
Absorption coefﬁcient 0.703 mm1
F(000) 1616
Crystal size 0.28  0.24  0.17 mm3
Theta range for data collection 2.26e27.00 .
Index ranges 18  h  19, 18  k  18,
22  l  22
Reﬂections collected 31490
Independent reﬂections 16184 [R(int) ¼ 0.0398]
Completeness to theta ¼ 27.00 99.8%
Absorption correction None
Reﬁnement method Full-matrix least-squares on F2
Data/restraints/parameters 16184/1/963
Goodness-of-ﬁt on F2 0.993
Final R indices [I > 2sigma(I)]a R1 ¼ 0.0698, wR2 ¼ 0.1714
R indices (all data) R1 ¼ 0.0978, wR2 ¼ 0.1878
Absolute structure parameter 0.043(13)
Largest diff. peak and hole 1.132 and 0.647 e Å3
a R1 ¼PjjFoj  jFcjj/PFo and wR2 ¼ {P[w(F02  Fc2)2]/P[w(Fo2)2]}1/2.
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measured.
The minimum inhibitory concentration (MIC) was determined
for each complex (only complexes 2, 3 and 4 and there parent li-
gands because of their signiﬁcant preliminary results) as the lowest
concentration which was capable of stopping bacterial growth.
Sequential dilutions of these complexes and their parent ligands in
DMSO in the range 8.5 mmol/L to 0.265 mmol/L, were prepared to
determine the MIC using the same previous procedure. When in-
hibition was present, the clear zone around the well for each
complex was compared with its parent ligands in the same plate
and the diameter of the inhibition zone was measured.3.6. Anti-malarial activity
3.6.1. In vitro testing for anti-malarial activity using semi-
quantitative method
The procedure for in vitro testing was carried out according to
Deharo et al. [19]. A mixture containing 50 mL of (0.5 mg/ml) hemin
chloride freshly dissolved in (DMSO), 100 mL of (0.5 M) sodium
acetate buffer (pH 4.4), and 50 mL of different concentrations of the
complex dissolved in pure water, was incubated in a normal non-
sterile 96-well ﬂat bottom plate at 37 C for 18e24 h. It is impor-
tant that the solutions be added to the plate in this order. The plate
was then centrifuged for 10 min at 4000 rpm. The supernatant was
removed and the pH of reaction was measured. The ﬁnal pH of the
mixture should be between (5.0e5.2). The wells were washed with
200 mL DMSO per well to remove free hemin chloride. The platewas
centrifuged again, discarding the supernatant afterwards. The re-
sidual b-hematin was then dissolved in 200 mL of 0.1 M NaOH to
form an FP that can be measured spectrophotometrically. Finally,
the absorbance was measured at 405 nm using ELISA reader Note,
ultra pure water was used as negative control; meanwhile chloro-
quine dissolved in ultra-pure water was used as positive control.3.6.2. Quantitative test
The method of Blauer and Akkawi was adopted for quantitative
test [21]. Freshly prepared stock solution of hemin chloride was
prepared by dissolving the salt in (DMSO) and incubated for 30 min
at 30 C stock solution of the complex used was prepared using
DMSO (0.5 M) sodium acetate buffer (pH 4.4) was also prepared,
the ﬁnal concentration of hemin and the complex in the reaction
were 0.2 and 0.4 mM respectively, the whole mixture was left for
18e24 h at 37 C without stirring. The total volume of the reaction
mixture was 32 ml, and the ﬁnal pH was 4.9e5.2.
Samples were centrifuged for 10 min using a serological (Jouan
B4) centrifuge. The supernatant was discarded and the precipitate
was washed with DMSO and quantitatively transferred to a Milli-
pore Swinnex 13 ﬁlter containing Whatman ﬁlter paper No. 50,
already lyophilized to a constant weight in freeze-drying machine
(Labconco Freezone). DMSO was passed slowly through the ﬁlter
until the ﬁltrate remained feebly colored and washed again with
ultra-pure water. The remaining was then lyophilized to a constant
weight.
4. Conclusion
Six zinc naproxen complexes were prepared and fully charac-
terized by IR, UVeVis, 1H NMR, 13C{1H} NMR spectroscopy. X-ray
crystal structure for complex 3 was also determined.
These complexes exhibit variant anti-bacterial activity against the
tested bacterial species. Complex 2 showed lower anti-bacterial ac-
tivity against all available bacterial species when compared to 1,10-
phenanthroline ligand. Complex 2 was the only complex that
showedanti-bacterial activityagainst P. aeruginosa, whichmaybedue
to the complexation of the active 1,10-phenathroline parent ligand.
Complex 3 showed higher anti-bacterial activity against G bacteria
compared to 2,9-dimethyl-1,10-phenanthroline ligand, but this ligand
showed higher anti-bacterial activity against Gþ than complex 3.
Complex 3 showed very high inhibition activity on the forma-
tion of the b-hematin and it has the potential to be further devel-
oped as an effective anti-malarial drug.
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